NCT04163874View on ClinicalTrials.gov

Alleviating Carbohydrate Counting for Patients With Type 1 Diabetes Using a Novel Insulin-plus-pramlintide Artificial Pancreas

NACompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

February 14, 2020

Primary Completion Date

January 30, 2022

Study Completion Date

January 30, 2022

Conditions
Type 1 DiabetesType 1 Diabetes MellitusHyperglycemia, Postprandial
Interventions
DRUG

Fiasp

Fiasp Insulin delivered in a basal-bolus manner.

DRUG

Pramlintide Acetate

Pramlintide delivered in a basal-bolus manner with a fixed ratio with insulin.

DRUG

Placebo

Placebo delivered in a basal-bolus manner with a fixed ratio with insulin.

DEVICE

Artificial Pancreas

Tandem insulin pump, dexcom G5 sensor, Nexus 5 cellphone running the iMAP algorithm.

Trial Locations (1)

H3A 2B1

3555 University Street, Montreal

Sponsors
All Listed Sponsors
collaborator

Juvenile Diabetes Research Foundation

OTHER

lead

McGill University

OTHER